Neumora Therapeutics is trading 10.08% down at $0.70 on September 23, with no new catalyst identified.
- The decline follows the September 22 rebound; no company-specific announcement, clinical update, earnings release, or analyst action has been identified for September 23.
- Available coverage mainly references earlier navacaprant trial setbacks and legal-investigation headlines. Broader markets are weaker, but biotechnology is outperforming, leaving the decline unexplained.